Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KLRS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | Samsara BioCapital, L.P. 10% owner | KLRS Kalaris Therapeutics, Inc. | Buy | 244,300 | $4.83 | $1.2M Buy | Form 4 ↗ |
| Mar 20, 2026 | Brett R. Hagen Chief Accounting Officer | KLRS Kalaris Therapeutics, Inc. | Sale | 1,915 | $6.72 | $12.9K Sale | Form 4 ↗ |
| Dec 18, 2025 | Samsara Opportunity Fund, L.P. 10% owner | KLRS Kalaris Therapeutics, Inc. | Buy | 479,847 | $10.42 | $5.0M Buy | Form 4 ↗ |
| Mar 26, 2025 | Brett R. Hagen Chief Accounting Officer | KLRS Kalaris Therapeutics, Inc. | Sale | 907 | $8.97 | $8,136 Sale | Form 4 ↗ |
| Feb 21, 2025 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 303 | $10.08 | $3,054 Sale | Form 4 ↗ |
| Feb 21, 2025 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 96 | $10.08 | $968 Sale | Form 4 ↗ |
| Feb 21, 2025 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 106 | $10.08 | $1,068 Sale | Form 4 ↗ |
| Jan 23, 2025 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 5 | $9.94 | $49.7 Sale | Form 4 ↗ |
| Jan 23, 2025 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 47 | $9.45 | $444 Sale | Form 4 ↗ |
| Jan 23, 2025 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 4 | $9.94 | $39.76 Sale | Form 4 ↗ |
| Jan 23, 2025 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 32 | $9.45 | $302 Sale | Form 4 ↗ |
| Jan 23, 2025 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 13 | $9.94 | $129 Sale | Form 4 ↗ |
| Jan 23, 2025 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 116 | $9.45 | $1,096 Sale | Form 4 ↗ |
| Jan 10, 2025 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 409 | $0.44 | $180 Sale | Form 4 ↗ |
| Jan 10, 2025 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 332 | $0.44 | $146 Sale | Form 4 ↗ |
| Jan 10, 2025 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 979 | $0.44 | $431 Sale | Form 4 ↗ |
| Nov 19, 2024 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 554 | $0.55 | $305 Sale | Form 4 ↗ |
| Nov 19, 2024 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 3,186 | $0.55 | $1,752 Sale | Form 4 ↗ |
| Nov 19, 2024 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 432 | $0.55 | $238 Sale | Form 4 ↗ |
| Nov 19, 2024 | Diana Brainard Chief Executive Officer, Director | ALVR Kalaris Therapeutics, Inc. | Sale | 8,706 | $0.55 | $4,788 Sale | Form 4 ↗ |
| Nov 5, 2024 | Diana Brainard Chief Executive Officer, Director | ALVR Kalaris Therapeutics, Inc. | Sale | 10,609 | $0.86 | $9,124 Sale | Form 4 ↗ |
| Nov 5, 2024 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 2,272 | $0.86 | $1,954 Sale | Form 4 ↗ |
| Nov 5, 2024 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 1,655 | $0.86 | $1,423 Sale | Form 4 ↗ |
| Nov 5, 2024 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 5,136 | $0.86 | $4,417 Sale | Form 4 ↗ |
| Oct 22, 2024 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 1,882 | $0.77 | $1,449 Sale | Form 4 ↗ |
| Oct 22, 2024 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 486 | $0.77 | $374 Sale | Form 4 ↗ |
| Oct 22, 2024 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 766 | $0.77 | $590 Sale | Form 4 ↗ |
| Oct 21, 2024 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 1,546 | $0.78 | $1,206 Sale | Form 4 ↗ |
| Oct 21, 2024 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 479 | $0.78 | $374 Sale | Form 4 ↗ |
| Oct 21, 2024 | Diana Brainard Chief Executive Officer, Director | ALVR Kalaris Therapeutics, Inc. | Sale | 9,752 | $0.78 | $7,607 Sale | Form 4 ↗ |
| Oct 21, 2024 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 635 | $0.78 | $495 Sale | Form 4 ↗ |
| Oct 3, 2024 | Vikas Sinha See Remarks, Director, 10% owner | ALVR Kalaris Therapeutics, Inc. | Sale | 940 | $0.81 | $761 Sale | Form 4 ↗ |
| Oct 3, 2024 | Edward Miller General Counsel | ALVR Kalaris Therapeutics, Inc. | Sale | 377 | $0.81 | $305 Sale | Form 4 ↗ |
| Oct 3, 2024 | Diana Brainard Chief Executive Officer, Director | ALVR Kalaris Therapeutics, Inc. | Sale | 1,493 | $0.81 | $1,209 Sale | Form 4 ↗ |
| Oct 3, 2024 | Brett R. Hagen Chief Accounting Officer | ALVR Kalaris Therapeutics, Inc. | Sale | 301 | $0.81 | $244 Sale | Form 4 ↗ |
35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 9:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances